SCIENTIFIC PROGRAMME Friday, 9 May 2025
HT-15 Hot Topic Session 15:00 – 16:30
HT-17 Hot Topic Session 15:00 – 16:30
North Hall
South Hall 2B Novel biological targets and treatment approaches in ADHD Chairs: Sarah Kittel-Schneider, Ireland Katya Rubia, United Kingdom 001 Patients in a dish: In-vitro models as tools to investigate the etiology of ADHD, leading to
ADHD and substance use disorders Chairs: Martin Gignac, Canada Brooke Molina, USA 001
ADHD and substance use disorders: A frequent comorbidity Martin Gignac, Canada The CADDRA ADHD and Substance Use Program Samuel Chang, Canada ADHD and substance use disorder treatment guidelines Mathias Luderer, Germany Psychostimulant medication for ADHD and risk of harmful substance use and diversion: Adolescent attitudes and long-term outcomes and physician clinical practice strategies Brooke Molina, USA
new treatment options Edna Grünblatt, Switzerland
002
002
T he impact of the gut microbiome in the patho- genesis of ADHD and therapeutic approaches targeting the gut microbiome Sarah Kittel-Schneider, Ireland Transcranial direct current stimulation as an option to normalize inhibitory-excitatory dys- balance in ADHD patients Maria Strauß, Germany Targeting right prefrontal cortex with fMRI- Neurofeedback and brain stimulation in ADHD Katya Rubia, United Kingdom
003
003
004
004
HT-16 Hot Topic Session 15:00 – 16:30
South Hall 2A Assessment and management of ADHD in Autism Spectrum Disorders Chairs: Jan K. Buitelaar, The Netherlands Susan Young, United Kingdom 001 The neuroanatomical substrates of autism and ADHD and their link to putative genomic underpinnings Jan K. Buitelaar, The Netherlands
ECSAS-01 Early Career Scientist Award Symposium 15:00 – 16:30 Club A Early Career Scientist Award Symposium dedicated to Joseph Sergeant Chairs: Tobias Banaschewski, Germany Sven Bölte, Sweden 001 W orking to close the academic achievement gap in young children with ADHD Jamie Spiegel, USA P. Graziano 002 Emotional dysregulation and suicidal spectrum behaviors in adults with ADHD Amalie Austgulen, Norway A. Høberg, A. J. Lundervold, T. A. Hegvik, J. Haavik 003 The impact of increased ADHD prescribing on real-world outcomes: A Swedish self- controlled case series study Lin Li, Sweden D. Coghill, A. Sjölander, H. Yao, L. Zhang, R. K. Halkola, I. Brikell, P. Lichtenstein, B. M. D’Onofrio, H. Larsson, Z. Chang
002
ADHD and autism symptoms in youth: A net- work analysis Guilherme Polanczyk, Brazil Assessing the contribution of measures of attention and executive function to diagnosis of ADHD or autism Kelsey Harkness, Canada Guidance for identification and treatment of individuals with ADHD and Autism Spectrum Disorder based upon expert consensus Susan Young, United Kingdom
003
004
004
Striatal proteomics in THRSP-overexpressing mice reveals Snap25 dysregulation, dopa- minergic impairments, and methylphenidate response in ADHD-PI Raly James Custodio, Germany L. Sayson, A. Cho, H. Jung, D. Ortiz, H. Lee, E. Alyan, E. Wascher, S. Getzmann, M. Kim, K. Kim
28
Made with FlippingBook Digital Publishing Software